Eyepoint pharmaceuticals Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Eyepoint pharmaceuticals Contact Number

Contact EyePoint Pharmaceuticals

5 hours ago Eyepointpharma.com Show details

833.393.7646Contact Us Please provide the following information to contact our team. EyePoint Pharmaceuticals, Inc. 480 Pleasant Street, Suite A-210Watertown, MA 02472United States p. 1.833.EyePoint (1.833.393.7646)f. 617.926.5050

Category: Contact SupportShow more

Home EyePoint Pharmaceuticals

7 hours ago Eyepointpharma.com Show details

EyePoint Pharmaceuticals utilizes science and innovation to develop new solutions that can create a lifetime worth seeing. Every patient is unique, but all patients have a shared vision of the future. A future of night skies filled with stars, faces of loved ones, and the moments that become memories. EyePoint Pharmaceuticals utilizes science

Category: Home PhoneShow more

EyePoint Pharmaceuticals Crunchbase Company Profile

7 hours ago Crunchbase.com Show details

(617) 926-5000Legal Name EyePoint Pharmaceuticals, Inc. Stock Symbol NASDAQ:EYPT. Company Type For Profit. Contact Email [email protected] Phone Number (617) 926-5000. EyePoint Pharmaceuticals develops tiny, sustained-release drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. The company have developed three

Founded: Jul 01, 2007
Location: Watertown, Massachusetts

Category: Contact NumberShow more

EyePoint Pharmaceuticals Overview, News & …

5 hours ago Zoominfo.com Show details

(617) 926-5000EyePoint Pharmaceuticals to Present Data at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting WATERTOWN, Mass., Sept. 17, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today …

Employees: 84
Phone: (617) 926-5000
Location: 480 Pleasant St, Watertown, 02472, Massachusetts

Category: Contact NumberShow more

EyePoint Pharmaceuticals, Inc. (EYPT) Company Profile

6 hours ago Stockanalysis.com Show details

Company profile for EyePoint Pharmaceuticals, Inc. (EYPT) with a description, list of executives, contact details and other key facts. Company profile for EyePoint Pharmaceuticals, Inc. (EYPT) with a description, list of executives, contact details and other key facts. CUSIP Number: 30233G100: ISIN Number: US30233G2093: Employer ID: 26

Category: Contact NumberShow more

EyePoint Pharmaceuticals Company Profile Office

4 hours ago Craft.co Show details

EyePoint Pharmaceuticals has 84 employees at their 1 location and $34.44 M in annual revenue in FY 2020. See insights on EyePoint Pharmaceuticals including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.

Category: Contact NumberShow more

8K: EyePoint Pharmaceuticals, Inc. MarketWatch

5 hours ago Marketwatch.com Show details

021-11-01EyePoint Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) File

Category: Contact NumberShow more

EyePoint Pharmaceuticals Reports Positive Interim Safety

8 hours ago Britishherald.com Show details

WATERTOWN – EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced six-month interim data from the “Durasert ® and Vorolanib in Ophthalmology” (DAVIO) Phase 1 clinical trial of EYP-1901, a bioerodible sustained delivery …

Category: Contact NumberShow more

EyePoint Pharmaceuticals Reports Positive Interim Safety

9 hours ago Pipelinereview.com Show details

WATERTOWN, MA, USA I November 13, 2021 I EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced six-month interim data from the "Durasert ® and Vorolanib in Ophthalmology" (DAVIO) Phase 1

Category: Contact NumberShow more

EyePoint Pharmaceuticals to Host Conference Call

1 hours ago Finance.yahoo.com Show details

WATERTOWN, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the

Category: Contact NumberShow more

EyePoint Pharmaceuticals to Present Data at the American

5 hours ago Investors.eyepointpharma.com Show details

WATERTOWN, Mass., Sept. 17, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that a late-breaking abstract highlighting topline data for the Phase 1 DAVIO trial of EYP-1901 in wet …

Category: Contact NumberShow more

Paul Ashton, Former Director, President & Chief Executive

8 hours ago Relationshipscience.com Show details

EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercializing of ophthalmic products. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

Category: Contact NumberShow more

EyePoint Pharmaceuticals Announces Closing of $115.4

8 hours ago Biospace.com Show details

WATERTOWN, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the closing of the previously announced underwritten public offering of 5,122,273 shares …

Category: Contact NumberShow more

EyePoint Pharmaceuticals Reports Positive Interim Safety

5 hours ago Finance.yahoo.com Show details

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today

Category: Contact NumberShow more

First in Human Study to Evaluate the Safety and

7 hours ago Clinicaltrials.gov Show details

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04747197

Category: Contact NumberShow more

Investor Relations EyePoint Pharmaceuticals

6 hours ago Investors.eyepointpharma.com Show details

Investor Relations. EyePoint Pharmaceuticals, Inc. (Nasdaq:EYPT) is a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious eye disorders. The Company’s pipeline leverages its proprietary Durasert ® technology for extended intraocular drug delivery

Category: Contact NumberShow more

EyePoint Pharmaceuticals Institutional Ownership

Just Now Marketbeat.com Show details

Of the 61 institutional investors that purchased EyePoint Pharmaceuticals stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Franklin Resources Inc. ($5.99M), RA Capital Management L.P. ($2.21M), Suvretta Capital Management LLC ($1.51M), BlackRock Inc. ($1.22M), Janus Henderson Group PLC ($0.72M), State Street Corp …

Category: Contact NumberShow more

EyePoint Pharmaceuticals Announces Pricing of Public

6 hours ago Globenewswire.com Show details

About EyePoint Pharmaceuticals. EyePoint Pharmaceuticals (Nasdaq:EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients

Category: Contact NumberShow more

EyePoint Pharmaceuticals, Inc. (EYPT) Stock Price, News

Just Now Stockstelegraph.com Show details

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) stock price is $17.07 as of the last check on Wednesday, Nov 24 2021. During the trading session, EYPT stock reached the peak price of $17.42 while $16.64 was the lowest point it dropped to.

Category: Contact NumberShow more

EyePoint Pharmaceuticals Announces Pricing of Public

6 hours ago Benzinga.com Show details

EyePoint Pharmaceuticals (NASDAQ:EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of …

Category: Contact NumberShow more

EyePoint Pharmaceuticals Appoints Jay S. Duker, M.D. as

9 hours ago Biospace.com Show details

WATERTOWN, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced the appointment of Jay S. Duker, M.D. as Chief Operating Officer (COO). Dr. Duker joined EyePoint

Category: Contact NumberShow more

PostOperative Ocular Steroid Treatment DEXYCU

9 hours ago Dexycu.com Show details

DEXYCU ® (dexamethasone intraocular suspension) 9% full U.S. Prescribing Information. EyePoint Pharmaceuticals, Inc. June 2020. 2. Data on file. EyePoint Pharmaceuticals, Inc. 3. Donnenfeld E, Holland E. Dexamethasone intracameral drug-delivery suspension for inflammation associated with cataract surgery: a randomized, placebo-controlled

Category: Contact NumberShow more

Uveitis Treatment Fluocinolone acetonide intravitreal

8 hours ago Yutiq.com Show details

833-393-7646480 Pleasant Street Suite B300 Watertown, MA 02472 1-833-EyePoint (1-833-393-7646)

Category: Contact NumberShow more

CRG Portfolio Eyepoint Pharmaceuticals

2 hours ago Crglp.com Show details

Watertown, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the closing of an underwritten public offering of 10,465,000 shares of its common stock at a public offering price of $11.00 per

Category: Contact NumberShow more

Careers EyePoint Pharmaceuticals, Inc. EyePoint

1 hours ago Careers-eyepointpharma.icims.com Show details

Welcome to the Careers Center for EyePoint Pharmaceuticals, Inc.. Please browse all of our available job and career opportunities. Apply to any positions you believe you are a fit for and contact us today!

Category: Contact NumberShow more

EyePoint Pharmaceuticals Reports Positive Interim Safety

2 hours ago Marketscreener.com Show details

WATERTOWN, Mass. - EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, announced six-month interim data from the 'Durasert and Vorolanib in Ophthalmology' (DAVIO) Phase 1 clinical trial of EYP-1901, a bioerodible sustained …

Category: Contact NumberShow more

Can Eyepoint Pharmaceuticals Inc (EYPT) Stock Rise to the

2 hours ago Investorsobserver.com Show details

Eyepoint Pharmaceuticals Inc (EYPT) stock is up 17.15% while the S&P 500 has fallen -0.33% as of 10:01 AM on Wednesday, Nov 17. EYPT has gained $2.41 from the previous closing price of $14.05 on volume of 896,737 shares.

Category: Contact NumberShow more

EyePoint Pharmaceuticals, Inc. (Form: 8K, Received: 12/08

2 hours ago Content.edgar-online.com Show details

590-20-0563EyePoint Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 480 Pleasant Street Watertown, MA 02472 (Address of Principal Executive Offices, and Zip Code) (617) 926-5000 Registrant’s

Category: Contact NumberShow more

8K SEC

1 hours ago Sec.gov Show details

On October 15, 2018, EyePoint Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration approved YUTIQ™ (fluocinolone acetonide intravitreal implant) for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by

Category: Contact NumberShow more

Access and Reimbursement Support Resources YUTIQ®

9 hours ago Yutiq.com Show details

833-393-7646Submit a patient through the EyePoint Assist HCP Portal. The EyePoint Assist HCP Portal allows you to submit patients for a benefits investigation, confirm insurance eligibility, and gain access to financial and reimbursement support. To learn more, call 1-833-EyePoint (1-833-393-7646) for assistance.

Category: Support NumberShow more

MidDay Market Update: StoneCo Drops After Q3 Earnings

5 hours ago Benzinga.com Show details

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) shares were also up, gaining 27% to $17.79. EyePoint Pharmaceuticals priced an underwritten public …

Category: Contact NumberShow more

EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on

4 hours ago Seekingalpha.com Show details

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q3 2021 Earnings Conference Call November 03, 2021 08:30 A.M.

Category: Contact NumberShow more

eypt8k_20200805.htm SEC

7 hours ago Sec.gov Show details

122 26-2774EyePoint Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction. of …

Category: Contact NumberShow more

Eyepoint Pharmaceuticals Inc (EYPT) is down 3.70% Thursday

8 hours ago Investorsobserver.com Show details

Eyepoint Pharmaceuticals Inc has a Long-Term Technical rank of 100. This means that trading over the last 200 trading days has placed the company in the upper half of stocks with 0% of the market scoring higher. In the Biotechnology industry which is number 139 by this metric, EYPT ranks better than 100% of stocks.

Category: Contact NumberShow more

EyePoint appoints Duker chief operating officer

8 hours ago Healio.com Show details

If you continue to have this issue please contact [email protected] EyePoint Pharmaceuticals has announced the appointment of Jay S. Duker, MD, as chief operating officer, according to

Category: Contact NumberShow more

MidAfternoon Market Update: Dow Falls 200 Points

4 hours ago Markets.businessinsider.com Show details

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) shares were also up, gaining 24% to $17.36. EyePoint Pharmaceuticals priced an underwritten public …

Category: Contact NumberShow more

EyePoint Pharmaceuticals (EYPT) stock forecast for 2024

4 hours ago Pandaforecast.com Show details

Target values for the price of one EyePoint Pharmaceuticals share for Feb 2024. The weighted average target price per EyePoint Pharmaceuticals share in Feb 2024 is: 20.61. In Feb, the negative dynamics for Momo shares will prevail with possible monthly volatility of 16.963% volatility is expected. Pessimistic target level: 19.55.

Category: Contact NumberShow more

EYPT Eyepoint Pharmaceuticals Stock Price Barchart.com

3 hours ago Barchart.com Show details

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -324.44% and -70.39%, respectively, for the quarter ended December 2020. Do the numbers hold clues to …

Category: Contact NumberShow more

EYPT EyePoint Pharmaceuticals Inc. Analyst Estimates

5 hours ago Marketwatch.com Show details

EyePoint Pharmaceuticals Inc. analyst estimates, including EYPT earnings per share estimates and analyst recommendations.

Category: Contact NumberShow more

Senior/Program Manager Job in Watertown, MA at EyePoint

5 hours ago Ziprecruiter.com Show details

EyePoint is seeking an experienced R&D Sr. /Program Manager to manage multiple projects at various stages of the drug development lifecycle. This position will report directly to the Sr Director, Portfolio Management. This position has the flexibility of working a hybrid schedule, 3 days onsite at our Watertown, MA site and 2 days remotely.

Category: Contact NumberShow more

THE ROLE OF INTRACAMERAL ANTIINFLAMMATORY AGENTS

9 hours ago Nyee.edu Show details

212-870-8127unrestricted educational grant from EyePoint Pharmaceuticals. 50.2% of patients applied the correct number of drops, and 4 patients with CME Provider Contact Information For questions about this activity, call 212-870-8127. TO OBTAIN AMA PRA CATEGORY 1 CREDIT™

Category: Contact NumberShow more

Sr. Scientist PreClinical Pharmacology Job in Watertown

2 hours ago Ziprecruiter.com Show details

Overview. See Your Future with EyePoint Pharmaceuticals. We are proud to be named a winner of the 2021 Deloitte Technology Fast 500 award, which recognizes the most innovative, fastest-growing companies in North America.

Category: Contact NumberShow more

EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Lags

1 hours ago Msn.com Show details

EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.47. …

Category: Contact NumberShow more

DailyMed YUTIQ fluocinolone acetonide implant

1 hours ago Dailymed.nlm.nih.gov Show details

879-136-01YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg is supplied in a sterile single-dose preloaded applicator with a 25-gauge needle, packaged in a sealed sterile foil pouch inside a sealed Tyvek pouch inside a carton box. NDC 71879-136-01.

Category: Contact NumberShow more

EYPT EyePoint Pharmaceuticals Inc. Stock Price & News WSJ

3 hours ago Wsj.com Show details

News EyePoint Pharmaceuticals Inc.EYPT. No news for in the past two years. Key Stock Data. P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the

Category: Contact NumberShow more

EYPT 13F Hedge Fund and Asset Management Owners

4 hours ago Whalewisdom.com Show details

480 PLEASANT STREET WATERTOWN, MA 02472. EYP-1901 is a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment for wet age-related macular degeneration. EYP-1901 leverages a bioerodible formulation of EyePoint's proprietary Durasert® sustained release technology with vorolanib, a tyrosine kinase inhibitor.

Category: Contact NumberShow more

EYPT Stock Forecast, Price & News (EyePoint Pharmaceuticals)

6 hours ago Marketbeat.com Show details

(617) 926-5000How can I contact EyePoint Pharmaceuticals? EyePoint Pharmaceuticals' mailing address is 480 PLEASANT STREET SUITE B300, WATERTOWN MA, 02472 . The company can be reached via phone at (617) 926-5000 , via email at [email protected] , or via fax at 617-926-5050 .

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Brand New Updated

Frequently Asked Questions

Who is eyeeyepoint pharmaceuticals?

EyePoint Pharmaceuticals, Inc., is a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious eye disorders.

What is EyePoint Pharmaceuticals' (Eypt) Q4 Earnings Report?

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) posted its quarterly earnings data on Wednesday, August, 4th. The company reported ($0.35) earnings per share for the quarter, beating analysts' consensus estimates of ($0.45) by $0.10.

What are Wall Street's price targets for EyePoint Pharmaceuticals' stock?

4 Wall Street analysts have issued 1 year price targets for EyePoint Pharmaceuticals' stock. Their forecasts range from $8.50 to $25.00. On average, they anticipate EyePoint Pharmaceuticals' share price to reach $17.63 in the next year. This suggests a possible upside of 58.1% from the stock's current price.

How has EyePoint Pharmaceuticals' stock performed during covid-19?

EyePoint Pharmaceuticals' stock was trading at $10.50 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, EYPT stock has increased by 6.2% and is now trading at $11.15. View which stocks have been most impacted by COVID-19. When did EyePoint Pharmaceuticals' stock split?

Popular Brands

Essity
Engie
Eaton